Pulse Biosciences, Inc. PLSE
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 434.00K | 401.00K | 264.00K | 86.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 434.00K | 401.00K | 264.00K | 86.00K | -- |
| Cost of Revenue | 273.00K | 370.00K | 260.00K | 279.00K | -- |
| Gross Profit | 161.00K | 31.00K | 4.00K | -193.00K | -- |
| SG&A Expenses | 8.46M | 6.59M | 7.33M | 8.78M | 8.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.71M | 19.55M | 18.52M | 20.45M | 20.28M |
| Operating Income | -25.27M | -19.15M | -18.25M | -20.37M | -20.28M |
| Income Before Tax | -24.66M | -18.58M | -17.43M | -19.39M | -19.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.66M | -18.58M | -17.43M | -19.39M | -19.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.66M | -18.58M | -17.43M | -19.39M | -19.17M |
| EBIT | -25.27M | -19.15M | -18.25M | -20.37M | -20.28M |
| EBITDA | -25.02M | -18.90M | -17.99M | -20.11M | -20.00M |
| EPS Basic | -0.36 | -0.27 | -0.26 | -0.29 | -0.28 |
| Normalized Basic EPS | -0.22 | -0.17 | -0.16 | -0.18 | -0.18 |
| EPS Diluted | -0.36 | -0.27 | -0.26 | -0.29 | -0.28 |
| Normalized Diluted EPS | -0.22 | -0.17 | -0.16 | -0.18 | -0.18 |
| Average Basic Shares Outstanding | 69.20M | 67.99M | 67.79M | 67.39M | 67.28M |
| Average Diluted Shares Outstanding | 69.20M | 67.99M | 67.79M | 67.39M | 67.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |